Abstract
A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)-based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.
MeSH terms
-
Everolimus
-
Humans
-
Immunosuppressive Agents / pharmacology
-
Mechanistic Target of Rapamycin Complex 1
-
Models, Biological
-
Multiprotein Complexes
-
Phosphatidylinositol 3-Kinases / metabolism
-
Protein Binding / drug effects
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinases / metabolism*
-
Proteins
-
Signal Transduction / drug effects*
-
Sirolimus / analogs & derivatives
-
Sirolimus / pharmacology
-
TOR Serine-Threonine Kinases
-
Tacrolimus Binding Protein 1A / metabolism
-
Transcription Factors / metabolism
Substances
-
CRTC2 protein, human
-
Immunosuppressive Agents
-
Multiprotein Complexes
-
Protein Kinase Inhibitors
-
Proteins
-
Transcription Factors
-
ridaforolimus
-
temsirolimus
-
Everolimus
-
Protein Kinases
-
MTOR protein, human
-
Mechanistic Target of Rapamycin Complex 1
-
TOR Serine-Threonine Kinases
-
Tacrolimus Binding Protein 1A
-
Sirolimus